Gene Therapies May Offer Promising Mesothelioma Treatments than Radiation Therapy
Oncologists and other cancer doctors choose what type of treatment to prescribe for each patient. There are many options. There are no standard treatment option for asbestos cancer patients. This is due to the cancers high mortality rate, rareness, low treatment success rate, and small number of studies to provide meaningful statistics.
Mesothelioma patients have historically had a bleak outlook, but doctors have recently made progress. Treatments for cancer are traditionally surgery (taking out the tumor and surrounding tissue), radiation (killing the cancerous cells with radiation), and chemotherapy (poisoning the cancerous cells.) Each one of these methods have problems. Patients with mesothelioma have not responded well to traditional radiation therapy. In hopes to lessen damage to healthy tissue, researches are studying ways to aim radiation right at the tumor.
Surgery removes the mesothelial tissue around the tumor. It is a grueling surgery with unknown benefits to patients. The usual chemotherapy cocktails effective on other cancers are not effective on mesothelioma, and combinations of chemotherapy agents have been tried, but without much success. Similar to radiation, focus in research is focusing on treating the physical location of the tumor with emphasis on the pleural cavity.
The high-mortality rate for mesothelioma patients means cutting-edge techniques for cancer are tried out. These include biologic therapy such as the agent interleukin 2 and anti-angiogenesis drugs such as thalidomide. The new drug pemetrexed (brand name Alimta) has shown good results in extending life with mesotheliomas..
Before acting, oncologists review the stage of mesothelioma, position of the tumor, and age and health status of the patient. Two therapies that are extremely cutting-edge in fighting cancer are called photodynamic and gene therapy. Clinical trials using these techniques are being offered to some of those who have mesothelioma.






















